Medicare Unlikely To Embrace Cost Effectiveness In Early Price Negotiations – ICER’s Pearson

The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.

CMS' Approach To Valuing Drugs Remains To Be Seen • Source: Shutterstock

More from Market Access

More from Pink Sheet